Eiger BioPharmaceuticals, Inc. (EIGRQ) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
DELISTED
What happened to Eiger BioPharmaceuticals, Inc. (EIGRQ) stock?
Eiger BioPharmaceuticals, Inc. (EIGRQ) no longer trades on public markets. The figures below are historical and are not a current quote.
Market cap $12.6M is the value of all shares combined. Beta 2.78: the stock has moved about 178% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Eiger BioPharmaceuticals, Inc. (EIGRQ). Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing therapies for hepatitis delta virus (HDV) and other serious diseases. The company filed for Chapter 11 reorganization in April 2024. Market cap: $12.6M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for EIGRQ: EIGRQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates EIGRQ against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
EIGRQ: 1/2 scored disciplines lean bearish. Dominant signal: Jim Simons bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Eiger BioPharmaceuticals, Inc. (EIGRQ) Healthcare & Pipeline Overview
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company specializing in therapies for hepatitis delta virus (HDV) and rare diseases like Hutchinson-Gilford progeria syndrome. Their lead product, Zokinvy, addresses progeria, while Lonafarnib targets HDV. The company is currently navigating Chapter 11 reorganization.
What Is the Investment Thesis for EIGRQ?
Eiger BioPharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity. The company's focus on rare diseases and HDV, a significant unmet medical need, offers potential for substantial growth if Lonafarnib gains regulatory approval and achieves commercial success. However, the recent Chapter 11 filing introduces significant uncertainty and risk. The company's gross margin of 95.1% indicates strong pricing power for its existing product, Zokinvy. Investors should closely monitor the bankruptcy proceedings, clinical trial outcomes for Lonafarnib and Peginterferon Lambda, and the company's ability to secure financing and restructure its operations. The company's beta of 2.78 suggests high volatility.
Based on FMP financials and quantitative analysis
EIGRQ Key Highlights
Market Cap of $12.6M reflects the company's distressed valuation following the Chapter 11 filing.
- Gross Margin of 95.1% indicates strong pricing power for Zokinvy, the company's commercialized product.
- P/E Ratio of -0.17 indicates the company is currently unprofitable.
- Profit Margin of -475.3% highlights the significant losses the company is incurring.
- Chapter 11 filing on April 1, 2024, introduces substantial risk and uncertainty for investors.
Who Are EIGRQ's Competitors?
EIGRQ is benchmarked below against 3 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CRPOF Ceapro Inc. | $0.17 | -13.04% | $13.3M | — |
| LVCLY Living Cell Technologies Limited | $0.03 | +24.39% | $11.4M | — |
| MGCLF MGC Pharmaceuticals Limited | $0.27 | +2.88% | $12.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are EIGRQ's Key Strengths?
Approved product (Zokinvy) generating revenue.
- Promising pipeline of product candidates targeting unmet medical needs.
- Expertise in developing therapies for rare diseases.
- Strong gross margin.
What Are EIGRQ's Weaknesses?
Chapter 11 bankruptcy filing.
- High operating losses and negative profit margin.
- Dependence on regulatory approval for pipeline products.
- Limited financial resources.
What Could Drive EIGRQ Stock Higher?
Potential regulatory approval of Lonafarnib for HDV.
- Progress in Chapter 11 bankruptcy proceedings.
- Clinical trial results for Peginterferon Lambda.
- Development of Avexitide for hyperinsulinism.
What Are the Key Risks for EIGRQ?
Chapter 11 bankruptcy proceedings and potential liquidation.
- Failure to obtain regulatory approval for pipeline products.
- Competition from other companies developing therapies for similar diseases.
- Inability to secure financing to fund operations.
- Limited liquidity and price volatility on the OTC market.
What Are the Growth Opportunities for EIGRQ?
- Lonafarnib Approval for HDV: Lonafarnib represents a significant growth opportunity for Eiger. HDV affects millions globally, and an approved therapy could generate substantial revenue. The Phase 3 clinical trials have been completed, and regulatory approval is the next step. The timeline for approval depends on the FDA review process, but potential approval could occur within the next 12-18 months, pending the resolution of the Chapter 11 reorganization.
- Peginterferon Lambda Development: Peginterferon Lambda is in clinical development for HDV and has also been investigated for COVID-19. The potential market for HDV treatment is substantial, and success in this area could drive significant growth. Further clinical trial results and regulatory decisions will determine the timeline and market potential.
- Avexitide for Hyperinsulinism: Avexitide, currently in Phase II development for congenital hyperinsulinism and post-bariatric hypoglycemia, addresses a niche market with limited treatment options. Successful clinical trials and regulatory approval could provide a valuable revenue stream. The timeline for commercialization depends on the progress of clinical trials and regulatory review.
- Expansion of Zokinvy Market: Zokinvy, approved for Hutchinson-Gilford progeria syndrome, can be expanded to new geographies and patient populations. While progeria is a rare disease, increasing awareness and diagnosis can drive growth. The company can also explore new formulations or indications for Zokinvy to further expand its market potential.
- Strategic Partnerships and Acquisitions: Eiger can pursue strategic partnerships or acquisitions to expand its product pipeline and market reach. Collaborations with other biotechnology companies or research institutions can accelerate the development of new therapies and provide access to new technologies. The company's Chapter 11 reorganization may impact its ability to pursue such opportunities in the near term.
What Are EIGRQ's Competitive Advantages?
- Patents and intellectual property protection for its therapies.
- Regulatory exclusivity for approved products, such as Zokinvy.
- Specialized expertise in developing therapies for rare diseases.
- Established relationships with key opinion leaders and patient advocacy groups.
What Does EIGRQ Do?
Eiger BioPharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for serious diseases with unmet medical needs. The company's lead product, Zokinvy, is approved for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Additionally, Eiger is developing Lonafarnib, an orally available farnesylation inhibitor, for the treatment of Hepatitis Delta Virus (HDV) infection, a disease with no approved therapies until recently. Peginterferon Lambda (lambda) is another product candidate in clinical development for HDV and has also been investigated for mild and moderate COVID-19. Avexitide is in Phase II development for congenital hyperinsulinism and post-bariatric hypoglycemia. Founded to address rare and orphan diseases, Eiger has evolved into a commercial-stage company with a focus on HDV and other serious conditions. Headquartered in Palo Alto, California, Eiger BioPharmaceuticals filed for Chapter 11 reorganization on April 1, 2024.
What Products and Services Does EIGRQ Offer?
- Develop and commercialize therapies for hepatitis delta virus (HDV).
- Offer Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome.
- Develop Lonafarnib, an orally available farnesylation inhibitor, for HDV infection.
- Develop Peginterferon Lambda (lambda) for HDV and COVID-19.
- Develop Avexitide for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia.
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
How Does EIGRQ Make Money?
- Develop and obtain regulatory approval for pharmaceutical products.
- Manufacture and market approved products directly or through partnerships.
- Generate revenue through the sale of pharmaceutical products.
- Invest in research and development to discover and develop new therapies.
What Industry Does EIGRQ Operate In?
Eiger BioPharmaceuticals operates within the biotechnology industry, a sector characterized by high research and development costs, lengthy regulatory approval processes, and significant market potential for successful therapies. The company focuses on niche markets such as rare diseases and HDV, where there are limited treatment options and significant unmet medical needs. The competitive landscape includes companies developing therapies for viral infections and rare genetic disorders. The biotechnology industry is driven by innovation and regulatory approvals, with market trends favoring targeted therapies and personalized medicine.
Who Are EIGRQ's Key Customers?
- Patients with Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies.
- Patients with Hepatitis Delta Virus (HDV) infection.
- Patients with congenital hyperinsulinism and post-bariatric hypoglycemia.
- Healthcare providers who prescribe and administer Eiger's therapies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price 5 days old
- ● No filing on record
- ● No analyst coverage
Company Profile
Eiger BioPharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO David Apelian. EIGRQ has traded publicly since 2014.
Eiger BioPharmaceuticals, Inc. (EIGRQ) Valuation Context
Valued at $12.6M, EIGRQ is classified as a micro-cap stock.
EIGRQ Financials
Bull Case vs Bear Case
Bull Case
- Approved product (Zokinvy) generating revenue.
- Promising pipeline of product candidates targeting unmet medical needs.
- Expertise in developing therapies for rare diseases.
- Strong gross margin.
Bear Case
- Chapter 11 bankruptcy filing.
- High operating losses and negative profit margin.
- Dependence on regulatory approval for pipeline products.
- Limited financial resources.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
EIGRQ Latest News
No recent news available for EIGRQ.
Leadership: David Apelian
CEO
David Apelian serves as the CEO of Eiger BioPharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on clinical development and commercialization. Prior to joining Eiger, he held leadership positions at various pharmaceutical companies, overseeing the development and launch of several successful products. His expertise spans multiple therapeutic areas, including infectious diseases and rare genetic disorders. He is responsible for managing 25 employees.
Track Record: Under David Apelian's leadership, Eiger BioPharmaceuticals has achieved key milestones, including the approval and commercialization of Zokinvy for Hutchinson-Gilford progeria syndrome. He has also overseen the advancement of Lonafarnib through Phase 3 clinical trials for HDV. The Chapter 11 filing occurred during his tenure, presenting a significant challenge for the company.
EIGRQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Eiger BioPharmaceuticals, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, are in financial distress, or have chosen not to comply with higher reporting standards. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for low trading volume and price volatility.
- Increased risk of fraud or manipulation.
- Uncertainty related to the company's Chapter 11 bankruptcy proceedings.
- Difficulty in obtaining reliable financial information.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their track record.
- Review the company's business plan and growth strategy.
- Evaluate the company's competitive position and market opportunities.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Commercial-stage biopharmaceutical company with an approved product (Zokinvy).
- Focus on developing therapies for serious diseases with unmet medical needs.
- Experienced management team with a background in the biopharmaceutical industry.
- Completion of Phase 3 clinical trials for Lonafarnib.
- Listing on the OTC market, indicating some level of public trading.
Common Questions About EIGRQ (Healthcare)
What happened to Eiger BioPharmaceuticals, Inc. (EIGRQ) stock?
Eiger BioPharmaceuticals, Inc. (EIGRQ) no longer trades on public markets. The figures below are historical and are not a current quote.
Can I still buy EIGRQ shares?
No. EIGRQ stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for EIGRQ elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before EIGRQ stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Eiger BioPharmaceuticals, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Eiger BioPharmaceuticals, Inc. do?
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for serious diseases with unmet medical needs, particularly hepatitis delta virus (HDV) and rare diseases.
What are the main risks for EIGRQ?
The primary risk for Eiger BioPharmaceuticals, Inc. is the ongoing Chapter 11 bankruptcy proceedings, which could result in significant losses for shareholders or even liquidation of the company.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company's Chapter 11 bankruptcy proceedings introduce significant uncertainty.